Technical Analysis for ACRS - Aclaris Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 1.21 | -0.82% | -0.01 |
ACRS closed unchanged on Tuesday, April 23, 2024, on 62 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. It ran into resistance at its 50 day moving average.
Earnings due: May 6
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Flat |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 50 DMA Resistance | Bearish | -0.82% | |
| 20 DMA Support | Bullish | -0.82% | |
| Bollinger Band Squeeze | Range Contraction | -0.82% | |
| NR7 | Range Contraction | -0.82% | |
| Gapped Up | Strength | -0.82% | |
| Fell Below 50 DMA | Bearish | -0.82% | |
| 20 DMA Support | Bullish | -0.82% | |
| Bollinger Band Squeeze | Range Contraction | -0.82% | |
| 20 DMA Support | Bullish | -2.42% | |
| 50 DMA Support | Bullish | -2.42% |
| Alert | Time |
|---|---|
| Fell Below Previous Day's Low | about 1 hour ago |
| 50 DMA Resistance | about 1 hour ago |
| 20 DMA Resistance | about 1 hour ago |
| 10 DMA Resistance | about 1 hour ago |
| Up 1% | about 1 hour ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/06/2024
Aclaris Therapeutics, Inc., a clinical-stage specialty pharmaceutical company, focuses on identifying, developing, and commercializing topical drugs to address various unmet needs in dermatology. Its lead drug candidate is A-101, a hydrogen peroxide topical solution that has completed three Phase II clinical trials for the treatment of seborrheic keratosis (SK), a common non-malignant skin tumor. The company is also developing A-101 as a prescription treatment for common warts; and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts. Aclaris Therapeutics, Inc. was founded in 2012 and is headquartered in Malvern, Pennsylvania.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Pharmaceutical Chemical Substances Hydrogen Dermatology Hydrogen Peroxide Stage Specialty Pharmaceutical Topical Medication Common Warts Keratosis
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Pharmaceutical Chemical Substances Hydrogen Dermatology Hydrogen Peroxide Stage Specialty Pharmaceutical Topical Medication Common Warts Keratosis
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 11.12 |
| 52 Week Low | 0.5902 |
| Average Volume | 1,034,253 |
| 200-Day Moving Average | 3.91 |
| 50-Day Moving Average | 1.22 |
| 20-Day Moving Average | 1.22 |
| 10-Day Moving Average | 1.22 |
| Average True Range | 0.07 |
| RSI (14) | 50.74 |
| ADX | 20.23 |
| +DI | 19.78 |
| -DI | 11.30 |
| Chandelier Exit (Long, 3 ATRs) | 1.12 |
| Chandelier Exit (Short, 3 ATRs) | 1.33 |
| Upper Bollinger Bands | 1.27 |
| Lower Bollinger Band | 1.17 |
| Percent B (%b) | 0.51 |
| BandWidth | 8.45 |
| MACD Line | 0.00 |
| MACD Signal Line | 0.00 |
| MACD Histogram | 0.0026 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.27 | ||||
| Resistance 3 (R3) | 1.28 | 1.26 | 1.26 | ||
| Resistance 2 (R2) | 1.26 | 1.25 | 1.26 | 1.26 | |
| Resistance 1 (R1) | 1.24 | 1.24 | 1.24 | 1.24 | 1.26 |
| Pivot Point | 1.23 | 1.23 | 1.23 | 1.23 | 1.23 |
| Support 1 (S1) | 1.21 | 1.21 | 1.20 | 1.20 | 1.18 |
| Support 2 (S2) | 1.19 | 1.21 | 1.19 | 1.18 | |
| Support 3 (S3) | 1.17 | 1.19 | 1.18 | ||
| Support 4 (S4) | 1.17 |
